SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of mobile and cell-derived therapeutics for the remedy of cardiovascular and pulmonary illnesses, as we speak introduced it would report its monetary outcomes for the three and 9 months ended September 30, 2022 and present a company replace by convention name on Wednesday, November 9, 2022 at 4:30 PM ET. Following administration’s formal remarks, there will likely be a question-and-answer session.
Participants can register for the convention by navigating to https://dpregister.com/sreg/10173215/f513fb1554. Please be aware that registered contributors will obtain their dial-in quantity upon registration. For those that haven’t registered, to hear to the decision by telephone, events inside the U.S. ought to name 1-833-316-0559 and worldwide callers ought to name 1-412-317-5730. All callers ought to dial in roughly 10 minutes prior to the scheduled begin time and ask to be joined into the BioCardia name. The convention name may also be accessible by means of a dwell webcast, which will be accessed by means of the next hyperlink: https://event.choruscall.com/mediaframe/webcast.html?webcastid=HNo6ZMgq.
A webcast replay of the decision will likely be accessible roughly one hour after the tip of the decision by means of February 9, 2023 on the above hyperlinks. A telephonic replay of the decision will likely be accessible by means of November 23, 2022 and could also be accessed by calling 1-877-344-7529 (home), 1-412-317-0888 (worldwide), or 855-669-9658 (Canada) by utilizing entry code 1510135.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell remedy for cardiovascular indications, and the NK1R+ allogeneic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary illnesses. These platforms underly 4 product candidates, every with the potential to meaningfully profit thousands and thousands of sufferers. Three of those investigational therapies are enabled by the Company’s proprietary biotherapeutic supply platforms, which the Company additionally selectively licenses to different biotherapeutic improvement companies. For extra info go to www.biocardia.com.
MEDIA CONTACT:
Anne Laluc
[email protected]
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
[email protected]
(650) 226-0120
